Last quarter (Q2 2023), Virpax Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Virpax Pharmaceuticals's net income was $-3.11M. See Virpax Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 6.20M	$ 21.85M	$ 12.03M	$ 4.20M	$ 3.18M	$ 2.63M
Operating Income	$ -12.41M	$ -21.85M	$ -12.03M	$ -4.20M	$ -3.18M	$ -2.63M
Net Non Operating Interest Income Expense	-	-	$ -92.82K	$ -147.93K	$ -124.64K	$ -14.98K
Other Income Expense	$ -298.97K	$ -194.41K	$ -62.26K	$ 4.00K	-	-
Pretax Income	$ -15.26M	$ -21.65M	$ -12.06M	$ -4.34M	$ -3.31M	$ -2.64M
Tax Provision	-	-	-	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -11.96M	$ -21.65M	$ -12.06M	$ -4.34M	$ -3.31M	$ -2.64M
Basic EPS	$ -1.31	$ -1.85	$ -1.81	$ -0.96	$ -0.67	$ -0.53
Diluted EPS	$ -1.75	$ -1.85	$ -1.81	$ -0.96	$ -0.67	$ -0.53
Basic Average Shares	$ 46.85M	$ 11.71M	$ 6.68M	$ 4.51M	$ 4.95M	$ 4.95M
Diluted Average Shares	$ 46.85M	$ 11.71M	$ 6.68M	$ 4.51M	$ 4.95M	$ 4.95M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 6.20M	$ 21.85M	$ 12.03M	$ 4.20M	$ 3.18M	$ 2.63M
Net Income From Continuing And Discontinued Operation	$ -15.26M	$ -21.65M	$ -12.06M	$ -4.34M	$ -3.31M	$ -2.64M
Normalized Income	$ -7.64M	-	-	$ -4.34M	$ -3.31M	$ -2.64M
Interest Expense	-	-	-	$ 147.93K	$ 124.64K	$ 14.98K
EBIT	$ -15.26M	$ -21.65M	$ -11.96M	$ -4.19M	$ -3.18M	$ -2.63M
EBITDA	$ -15.26M	$ -21.65M	$ -11.96M	$ -4.19M	$ -3.18M	$ -2.63M

Currency in USD

Virpax Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing